Evidence map›Paper›PMID 33082334›Full record

ArticleNature communications2020

WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion.

Irene Rodriguez-Hernandez, Oscar Maiques, Leonie Kohlhammer, Gaia Cantelli, Anna Perdrix-Rosell, Joanne Monger, Bruce Fanshawe, Victoria L Bridgeman, Sophia N Karagiannis, Rosa M Penin and 7 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 99 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Bleb expansion requires transient membrane invaginations that sequester curvature-preferring proteins.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Amoeboid cancer cells at a glance.Journal of cell science · 2026
    Review
  7. Amoeboid-mesenchymal transition and the proteolytic control of cancer invasion plasticity.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Unleashing Wnts: Wnt Ligands Fuel Cancer Spread.Journal of cancer biology · 2025
    Article
  17. Frizzled receptors: gatekeepers of Wnt signaling in development and disease.Frontiers in cell and developmental biology · 2025
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

Irene Rodriguez-HernandezBarts Cancer Institute, Queen Mary University of London, John Vane Science Building, Charterhouse Square, London, EC1M 6BQ, UK.ORCID 0000-0002-6487-452X
Oscar MaiquesBarts Cancer Institute, Queen Mary University of London, John Vane Science Building, Charterhouse Square, London, EC1M 6BQ, UK.
Leonie KohlhammerBarts Cancer Institute, Queen Mary University of London, John Vane Science Building, Charterhouse Square, London, EC1M 6BQ, UK.
Gaia CantelliRandall Division of Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London, SE1 1UL, UK.
Anna Perdrix-RosellBarts Cancer Institute, Queen Mary University of London, John Vane Science Building, Charterhouse Square, London, EC1M 6BQ, UK.
Joanne MongerBarts Cancer Institute, Queen Mary University of London, John Vane Science Building, Charterhouse Square, London, EC1M 6BQ, UK.
Bruce FanshaweRandall Division of Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London, SE1 1UL, UK.
Victoria L BridgemanTumour Host Interaction Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK.
Sophia N KaragiannisSt John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London and NIHR Biomedical Research Centre at Guy's and St Thomas' Hospitals and King's College London, London, SE1 9RT, UK.ORCID 0000-0002-4100-7810
Rosa M PeninDepartment of Pathology, Hospital Universitari de Bellvitge, IDIBELL, l'Hospitalet de Llobregat, 08908, Barcelona, Spain.
Joaquim MarcolvalDepartment of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, l'Hospitalet de Llobregat, 08908, Barcelona, Spain.
Rosa M MartiDepartment of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRB LleidaI, CIBERONC, 25198, Lleida, Spain.ORCID 0000-0001-6866-6114
Xavier Matias-GuiuDepartment of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, University of Lleida, IRB Lleida, CIBERONC, 25198, Lleida, Spain.ORCID 0000-0002-7201-6605
Gilbert O FruhwirthDepartment of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, Kings' College London, London, SE1 7EH, UK.ORCID 0000-0002-1438-2674
Jose L OrgazBarts Cancer Institute, Queen Mary University of London, John Vane Science Building, Charterhouse Square, London, EC1M 6BQ, UK.
Ilaria MalanchiTumour Host Interaction Laboratory, The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK.ORCID 0000-0003-4867-3311
Victoria Sanz-MorenoBarts Cancer Institute, Queen Mary University of London, John Vane Science Building, Charterhouse Square, London, EC1M 6BQ, UK. v.sanz-moreno@qmul.ac.uk.ORCID 0000-0002-5096-9456
Queen Mary University of London · GBBellvitge University Hospital · ESKing's College London · GBThe Francis Crick Institute · GBUniversitat de Lleida · ESDuke University · USSt Thomas' Hospital · GB

Funding

Cancer Research UK 21153Cancer Research UK 24478Cancer Research UK C10355/A15587Cancer Research UK C30122/A11527Cancer Research UK C30122/A15774Cancer Research UK C33043/A12065Cancer Research UK C33043/A24478Cancer Research UK C48390/A21153Cancer Research UK FC001112Department of Health IS-BRC-1215-20006Medical Research Council C97993HMedical Research Council FC001112Medical Research Council MR/L023091/1Wellcome Trust FC001112Wellcome Trust WT 203148/Z/16/Z
6 · The paper itself

Abstract

Melanoma is a highly aggressive tumour that can metastasize very early in disease progression. Notably, melanoma can disseminate using amoeboid invasive strategies. We show here that high Myosin II activity, high levels of ki-67 and high tumour-initiating abilities are characteristic of invasive amoeboid melanoma cells. Mechanistically, we find that WNT11-FZD7-DAAM1 activates Rho-ROCK1/2-Myosin II and plays a crucial role in regulating tumour-initiating potential, local invasion and distant metastasis formation. Importantly, amoeboid melanoma cells express both proliferative and invasive gene signatures. As such, invasive fronts of human and mouse melanomas are enriched in amoeboid cells that are also ki-67 positive. This pattern is further enhanced in metastatic lesions. We propose eradication of amoeboid melanoma cells after surgical removal as a therapeutic strategy.

Indexed as

AnimalsCell Transformation, NeoplasticFemaleFrizzled ReceptorsHumansMaleMelanomaMiceMice, SCIDMicrofilament ProteinsMyosin Type IINeoplasm Invasivenessrho-Associated Kinasesrho GTP-Binding ProteinsSignal TransductionWnt ProteinsDaam1 protein, mouseFrizzled ReceptorsFzd7 protein, mouseMicrofilament ProteinsMyosin Type IIrho-Associated Kinasesrho GTP-Binding ProteinsRock1 protein, mouseWnt11 protein, mouseWnt Proteins

Identifiers

PMID33082334
PMCPMC7575593
OpenAlexW3094124783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.